Cargando…

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies

Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach. Recommendations were developed by an internation...

Descripción completa

Detalles Bibliográficos
Autores principales:	DE BRUIN-WELLER, Marjolein, BIEDERMANN, Tilo, BISSONNETTE, Robert, DELEURAN, Mette, FOLEY, Peter, GIROLOMONI, Giampiero, HERCOGOVÁ, Jana, HONG, Chih-Ho, KATOH, Norito, PINK, Andrew E., RICHARD, Marie-Aleth, SHUMACK, Stephen, SILVESTRE, Juan F., WEIDINGER, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2021
Materias:	Clinical Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366686/ https://www.ncbi.nlm.nih.gov/pubmed/33491094 http://dx.doi.org/10.2340/00015555-3751

Ejemplares similares

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

Flare management in atopic dermatitis: from definition to treatment
por: Girolomoni, Giampiero, et al.
Publicado: (2022)

Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey
por: AUGUSTIN, Matthias, et al.
Publicado: (2022)

Atopic Dermatitis: Identification and Management of Complicating Factors
por: Tamagawa-Mineoka, Risa, et al.
Publicado: (2020)

Targeting IL-4 for the Treatment of Atopic Dermatitis
por: Chiricozzi, Andrea, et al.
Publicado: (2020)

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs
por: Zuberbier, Torsten, et al.
Publicado: (2023)

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2022)

Overview of Atopic Dermatitis in Different Ethnic Groups
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
por: de Bruin‐Weller, M., et al.
Publicado: (2020)

New Developments in Biomarkers for Atopic Dermatitis
por: Thijs, Judith L., et al.
Publicado: (2015)

Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature
por: Heilskov, Sofine, et al.
Publicado: (2020)

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2020)

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
por: Griffiths, Christopher, et al.
Publicado: (2021)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
por: ROGNER, Danielle, et al.
Publicado: (2022)

Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use
por: DELEURAN, Mette, et al.
Publicado: (2021)

Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants
por: Luger, Thomas, et al.
Publicado: (2015)

Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis
por: ACHTEN, Roselie, et al.
Publicado: (2023)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
por: Alexis, Andrew, et al.
Publicado: (2022)

Difficult to control atopic dermatitis
por: Darsow, Ulf, et al.
Publicado: (2013)

Exploratory analyses of biomarkers in blood and stratum corneum in patients with atopic dermatitis
por: Maruyama, Ayano, et al.
Publicado: (2022)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Food allergen sensitization pattern in adults in relation to severity of atopic dermatitis
por: Röckmann, Heike, et al.
Publicado: (2014)

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
por: Oosterhaven, Jart A.F., et al.
Publicado: (2019)

Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process
por: THYSSEN, Jacob P., et al.
Publicado: (2020)

Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation
por: Biedermann, Tilo, et al.
Publicado: (2015)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis
por: Maurelli, Martina, et al.
Publicado: (2023)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
por: Simpson, Eric L., et al.
Publicado: (2022)

Association Between Atopic Dermatitis and Educational Attainment in Denmark
por: Schmidt, Sigrun Alba Johannesdottir, et al.
Publicado: (2021)

The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis
por: ELSNER, Julie Sophie Hohwü, et al.
Publicado: (2020)

Measuring serum concentrations of interleukin-33 in atopic dermatitis is associated with potential false positive results
por: Nygaard, Uffe, et al.
Publicado: (2016)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Assessing patients’ characteristics and treatment patterns among children with atopic dermatitis
por: Geat, Davide, et al.
Publicado: (2021)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Consensus Update for Systemic Treatment of Atopic Dermatitis
por: Lee, Ji Hyun, et al.
Publicado: (2021)

Netherton syndrome plus atopic dermatitis: Two new genetic mutations in the same patient
por: Moar, Agata, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_icj5153itijkhenq96ocsp2g92